Benzinga | Nov 9, 2021 11:24AM EST

Stifel Upgrades eFFECTOR Therapeutics to Buy, Announces $20 Price Target

Stifel analyst Benjamin Burnett upgrades eFFECTOR Therapeutics (NASDAQ:EFTR) from Hold to Buy and announces $20 price target.